High Co. SA engages in the retail agencies, retail media, and retail activation businesses in France and Belgium. The company supports brands and retailers in implementing promotional activations with a model that integr…
Industry Peers
Advertising Agencies| Headline | Source | Time |
|---|---|---|
Older | ||
LLe Soleil | ||
TThe Media Leader | ||
LLSA | ||
European Penny Stocks To Watch In January 2026 As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are keeping a close watch on smaller companies that might offer unique opportunities. Penny stocks, despite their somewhat outdated name, remain an intriguing area of investment for those interested in potentially high-growth sectors. These stocks often represent smaller or newer companies that can provide a blend of affordability and growth... | ||
European Penny Stocks To Watch In December 2025 As European markets continue to show signs of steady economic growth, with the STOXX Europe 600 Index rising by 1.60%, investors are exploring diverse opportunities across the continent. Penny stocks, often representing smaller or newer companies, remain a compelling area for those seeking affordability and potential growth. Despite their historical connotations, these stocks can still offer significant value when they exhibit strong financials and promising business models. | ||
European Penny Stocks Under €80M Market Cap To Consider The European market has recently experienced a pullback, with the pan-European STOXX Europe 600 Index ending 1.24% lower amid concerns about overvaluation in artificial intelligence-related stocks. Despite these challenges, the search for promising investment opportunities continues, particularly among smaller companies that might not be on every investor's radar. While the term "penny stocks" may seem outdated, these smaller or newer companies can still offer significant growth potential... | ||
European Penny Stocks To Watch In September 2025 As the European markets experience a modest uptick, with major indices like the STOXX Europe 600 Index gaining ground amid expectations of U.S. interest rate cuts, investors are keenly observing how these developments might influence regional economic growth and inflation forecasts. Penny stocks, often representing smaller or newer companies, continue to capture attention due to their potential for growth at relatively low price points. Despite being considered a somewhat outdated term, penny... | ||
GL Events Valuation in Focus After Strong 61.7% Year-to-Date Rally Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really happening beneath the surface. GL Events is one of those names where, if you had blinked a year ago, you might have missed some serious upside. Over the past five years, the stock has delivered a remarkable 219.9% return, and it is up 103.9% over three years alone. Even with a recent pullback of... | ||
Heineken’s Strongbow adds NaviLens levels to packaging The cider brand has added a high-contrast NaviLens QR code to its cans. | ||
3 firms to lay off hundreds of North Jersey-based employees BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty | ||
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
Novartis to acquire Tourmaline Bio for $1.4 billion Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said. | ||
European Dividend Stocks To Consider: 3 Noteworthy Picks As European markets experience a boost from easing trade tensions and optimism surrounding potential U.S. interest rate cuts, investors are increasingly turning their attention to dividend stocks as a means of securing steady income amidst the fluctuating economic landscape. In this environment, selecting dividend stocks with strong fundamentals and reliable payout histories can offer stability and potential for growth, making them an attractive consideration for those looking to navigate the... | ||